Phase III trial with Nubeqa™ (darolutamide) in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

Bayer extends clinical development program for finerenone with Phase III study in children and adolescents with chronic kidney disease

New Phase III study to investigate expanded use of vericiguat in patients with chronic heart failure with reduced ejection fraction